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Background: Synovial sarcoma, X breakpoint 2 interacting protein (SSX2IP), which has been identified as an acute
myeloid leukemia associated antigen, is a potential target for leukemia immunotherapy. In rodents, its homologous
gene, ADIP, plays an important role in the regulation of cell adhesion and migration, underlying its potential role in
promoting metastasis of other cancers.
Methods: To investigate the correlation between the expression level of SSX2IP and the clinicopathologic factors of
hepatocellular carcinoma (HCC), 53 cases were studied by qPCR and statisted. To directly testing SSX2IP’s
contribution to HCC in animal models, 45 nude mice were enrolled in peritoneal spreading and liver metastasis
models. For the migration and invasion assays, cell culture experiments were performed using QCMTM 24-Well
Colorimetric Migration Assay Kit and Cell Invasion Assay Kit (Millipore). Moreover we examined the influence of
SSX2IP overexpression on the chemosensitivity of hepatocellular carcinoma cells to two most common
chemotherapy drugs (5-Fu and CDDP) using Cell counting kit-8 (CCK-8). The chemotherapeutic drugs sensitivity
was evaluated by IC50 parameter.
Results: Statistical analysis of clinical cases revealed that the SSX2IP high expression group had inclinations towards
larger tumor size, more tumor thrombus and shorter survival period, implying a strong correlation between the
expression level of SSX2IP and HCC tumorigenesis. Consistently in abdominal cavity metastasis and liver metastasis
models of immune-deficient mice, SSX2IP was able to promote the metastasis of hepatoma cells. At the cytological
level, SSX2IP stimulates the wound healing, metastasis and invasion of hepatoma cells, and reduces the sensitivity
of hepatoma cells to 5-Fu and CDDP.
Conclusions: Our results showed that SSX2IP promotes the development and metastasis of hepatocellular
carcinoma and contributes to the drug resistance of hepatoma cells, suggesting that SSX2IP is expected to become
a new diagnostic and prognostic marker and a new target of the treatment of hepatocellular carcinoma.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon malignant tumors, ranking the fifth of the global ma-
lignant tumor incidence and the third of cancer related
cause of death [1,2]. In China, hepatocellular carcinoma
incidence ranks second only to lung cancer and counts for
about half of the global number, thus people’s health and
life quality have been seriously affected. As the disease
symptom is not obvious, early diagnosis is difficult; most
of the patients have advanced cancer at the time of diag-
nosis, and the disease is easy to relapse even if the lesions
were resected. Although chemotherapy is an important
method in combined treatment of hepatocellular carcin-
oma, its effect becomes less unsatisfactory as hepatoma
cells from advanced cancer often develop resistance to
chemotherapeutic drugs. Therefore, identifying molecular
markers suitable for early diagnosis and new therapeutic
targets for treatment will greatly benefit the many HCC
patients around the world.
The SSX2IP gene is located on chromosome 1p22.3,
spanning 46 kb region and containing 14 exons [3]. The
locus has a higher frequency of deletions, amplifications
and translocations [4-6]. SSX2IP was originally identified
through its interaction with SSX2, a transcriptional re-
pressor [7], and was suggested to regulate the role of
SSX2 in testicular tissue and malignant cells [8]. Previ-
ous studies indicated that SSX2IP is an acute myeloid
leukemia-associated antigen, as analysis of clinical cases
showed that the expression of SSX2IP was identified in
the serum of 33% patients with acute myeloid leukaemia
(AML), but not in healthy volunteers [9]. SSX2IP ex-
pression was most apparent on the surface of myeloid
leukaemia cells in mitosis [10,11]. Several studies further
strengthened the argument that SSX2IP was an acute
myeloid leukemia-associated antigen and a potential im-
munotherapy target for leukemia [12-14]. So far, the role
of SSX2IP in other human tumors remains elusive.
Afadin DIL domain-interacting protein (ADIP) is the
homologous gene of SSX2IP in rodents, and the amino
acid sequences of ADIP in mouse and rat show 88% and
87% identity with SSX2IP respectively. Cytologically,
ADIP localizes at cell-cell adherens junctions and
promotes cell migration by activating Rac protein
through Vav2 [15,16]. All of the above characteristics are
closely related to the adhesion capacity and metastatic
characteristics. Given the functionality prompts of
SSX2IP and its homologue gene ADIP, we decided to ex-
plore the role of SSX2IP in the development and pro-
gression of hepatocellular carcinoma.
Methods
Cell culture and transfection
Human hepatocellular carcinoma cell lines SMMC-7721
and BEL-7402 were preserved in our institute. Briefly, cellswere grown in DMEM supplemented with 10% fetal calf
serum. Cells were maintained at 37°C with 5% CO2.
SSX2IP was constructed into pEGFP-C1 eukaryotic ex-
pression vector. We obtained stably transfected clones by
G418 selection (Promega, 800 μg/ml). A stable transfect-
ant of the pEGFP-C1 empty vector was used as a control.
Migration, invasion and scratch wound healing assays
For the cell migration assays, cell culture was performed
using QCMTM 24-Well Colorimetric Migration Assay
Kit (Millipore) according to the manufacturer’s
instructions. For the invasion assay, Cell Invasion Assay
Kit (Millipore) was used according to the manufacture’s
instructions. Cells (1 × 105) in 300 μl serum-free medium
were added to the upper chambers and cultured for
48 h. Non-migrating or non-invading cells were removed
with cottons swabs, Cells that migrated or invaded to
the bottom of the membrane were stained with the cell
stain buffer provided in the assay kit and counted under
microscope and photographed. Three independent
experiments were performed for the same conditions.
For the scratch wound healing assay, cells were cultured
in serum-free medium for 24 h and wounded with pip-
ette tips. Fresh medium was replaced. The wound clos-
ing procedure was observed for 48 h, and photographs
were taken every 24 h.
Nude mice study
Both peritoneal spreading and liver metastasis models were
observed. 4-week-old male BALB/C nude mice were
purchased from the Institute of Zoology, Chinese Academy
of Sciences of Shanghai. All experiments were performed
in accordance with the official recommendations of the
Chinese animal community. In peritoneal spreading ex-
periment, 5 mice were enrolled in each group. 1 × 106 cells
of BEL-7402, BEL-7402Vector and BEL-7402SSX2IP were
injected into each mouse. In liver metastasis study, 10 mice
were enrolled in each group. 1 × 106 cells of BEL-7402,
BEL-7402Vector and BEL-7402SSX2IP were injected into cau-
dal vena. 6 weeks after intraperitoneal injection, mice were
killed by cervical decapitation, the abdominal masses were
excised and fixed with buffered formalin for further mor-
phological analysis. 10 weeks after caudal vena injection,
mice were killed by cervical decapitation. The liver of mice
was examined carefully and the metastatic masses were
counted.
Chemotherapeutic drugs sensitivity analysis by cell
counting kit-8
Hepatocellular carcinoma cells (3 × 103 cells/well)
were seeded in 96-well plates and treated with
different chemotherapeutics 5-fluorouracil (5-Fu) and
Cis-diamminedichloroplatinum (CDDP) in different
concentrations for 72 h. Cell Counting Kit-8 (CCK-8,
Table 1 Relationship between SSX2IP expression level
and clinicopathologic variables in 53 HCC patients
Clinicopathologic
parameters
SSX2IP expression level P
Low (n = 21) High (n = 32)
Gender
Female 3 6 0.961
Male 18 26
Age
>50 11 19 0.615
≤50 10 13
Tumor size(cm)
>5 8 21 0.049
≤5 13 11
Tumor encapsulation
Complete 13 16 0.394
Incomplete 8 16
Tumor differentiation
I II 11 24 0.089
III IV 10 8
Tumor number
Single 17 27 1.000
Multiple 4 5
Lymph node invasion
No 20 29 0.928
Yes 1 3
Tumor thrombus
No 18 18 0.025
Yes 3 14
AFP(ng/mL)
≤400 5 12 0.296
>400 16 20
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cubation at 37°C, the coloring reaction was quantified by
an automatic plate reader (BIO.TEK, USA). Growth in-
hibitory effects were expressed as cell viability curve
(OriginPro 8.5.1, USA). The chemotherapeutic drugs
sensitivity was evaluated by IC50 parameter (inhibitory
concentration of 50% cells).
Patients
HCC tissues were collected from patients at Zhongshan
Hospital, Fudan University, after obtaining the subjects’
informed consent and with institutional review board
approval of the hospital.
mRNA expression analysis
Total RNA was extracted using Trizol solution (Invitrogen).
Reverse transcription was performed according to the
manufacturer’s instructions (Promega). qPCR was per-
formed in triplicate using the SYBR Green Mastermix on
the ABI Prism 7900 Sequence Detection System (Applied






Data were shown as mean ± SD. Statistically significant
differences were analyzed using Student t test, when
there were only two groups, multiple comparisons were
performed by one-way analysis of variance. For survival
analysis, Kaplan-Meier method was used. Log rank test
was used to analyze differences between statistical
significances. All statistical analyses were performed
using the SPSS 13.0 software (SPSS Inc, Chicago, IL,
USA). P < 0.05 was considered statistically significant.
Results
The expression levels of SSX2IP in HCC patients were
significantly correlated with tumor size, tumor
thrombosis and survival time
To examine the correlation between the expression level
of SSX2IP and clinicopathologic factors in HCC, 53
cases were statistically analysed. The clinical and patho-
logic characteristics of these cases were shown in Table 1.
Among them, 32 samples showed a ~2-fold up-regulation
of SSX2IP compared with the matched non-tumor
controls. These samples were classified as the high expres-
sion group, and the other 21 samples were classified as the
low expression group. Importantly, the SSX2IP high ex-
pression group had inclinations towards larger tumor size
and more tumor thrombus (P < 0.05). However, there were
no significant relationships with other clinicopathologic
factors. Notably, 51 out of 53 patients were re-interviewedwith a re-interview rate of 96%, Kaplan-Meier survival
analysis showed the patient survival time in SSX2IP high
expression group (n = 31) was significantly shorter than in
the low expression group (n = 20) (P = 0.004, Figure 1).
Taken together, our patient cases studies suggest that
SSX2IP may have a previously unrecognized role in
promoting hepatocellular carcinoma.
SSX2IP promotes peritoneal spreading and liver
metastasis of hepatocellular carcinoma cells in nude mice
To directly test the contribution of SSX2IP in HCC, we
carried out peritoneal spreading and liver metastatic
assays in mice models. A total of 45 nude mice were en-
rolled in these experiments, among which, 15 mice were
used for peritoneal spreading assay and 30 for liver
metastatic assay. The results were shown in Figure 2 and
summarized in Table 2 and Table 3. Strikingly, the peri-
toneal nodules were significantly enforced in SSX2IP
Figure 1 Kaplan-Meier survival analysis of SSX2IP expression level in 51 HCC patients. The survival time in SSX2IP high expression group
(n = 31) was shorter than in the low expression group (n = 20), the difference was significant (P = 0.004).
Figure 2 Effect of enforcing SSX2IP on peritoneal spreading and liver metastasis. 1 × 106 cells per mouse were injected into peritoneal
cavity or caudal vena. A. BEL-7402, BEL-7402Vector and BEL-7402SSX2IP, the three cell lines, were injected into the peritoneal cavity of nude mice.
6 weeks later, we took the photographs of the peritoneal nodles. B. The peritoneal nodles were significantly enforced in SSX2IP overexpression
group, compared with the parental cells and empty vector-transfected cells groups(6.2 ± 0.84 vs 2.6 ± 0.89, 2.4 ± 1.14, **P < 0.001). C. BEL-7402,
BEL-7402Vector and BEL-7402SSX2IP, the three cell lines, were injected into the caudal vena of nude mice. 10 weeks later, we took the photographs
of the nude mice liver. D. Statistical proportion of liver metastasis mice. In SSX2IP overexpression group, 7 out of 10 mice show tumorigenicity in
liver, which is significantly higher than that in parental and empty vector-transfected groups (2/10 and 1/10, P = 0.023).
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Table 2 Animal experiments for peritoneal spreading
Animal models Cells Cell numbers of injection Time Tumorigenicity P
Peritoneal spreading
Bel-7402 1 × 106 6 weeks 2.6 ± 0.89 P < 0.001
Bel-7402Vector 1 × 106 6 weeks 2.4 ± 1.14
Bel-7402SSX2IP 1 × 106 6 weeks 6.2 ± 0.84
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empty vector-transfected groups (6.2 ± 0.84 vs 2.6 ± 0.89,
2.4 ± 1.14, **P < 0.001, Figure 2A-B and Table 2). The
tumorigenicity of liver metastasis was also observed. In
SSX2IP overexpression group, 7 out of 10 mice showed
tumorigenicity in liver, which is significantly higher than
that in the parental group (2/10) and the empty vector-
transfected group (1/10) (P = 0.023, Figure 2C-D and
Table 3). The results clearly reveal a promoting role of
SSX2IP in hepatocellular carcinoma development.
SSX2IP enhances scratch wound healing ability of
hepatocellular carcinoma cells
We next examined the cytological effect of SSX2IP
on movement ability of HCC cells by scratch healing
assay. Consistent with our results from mice models,
SSX2IP overexpression cell lines SMMC-7721SSX2IP
and BEL-7402SSX2IP largely sealed the wound 48 h after
scratching, in contrast to the parental cells and empty
vector-transfected cells which were significantly less effi-
cient in healing, as indicated by the mean wound distances
(SMMC-7721 cell line groups: 170.83 ± 36.96 μm vs
516.67 ± 25.57 μm and 525.00 ± 31.92 μm, **P < 0.001.
BEL-7402 cell line groups: 183.33 ± 49.07 μm vs 312.50 ±
25.00 μm and 329.17 ± 15.96 μm, **P < 0.001, Figure 3).
SSX2IP promotes migration and invasion of
hepatocellular carcinoma cells
In order to further assess the influence of SSX2IP on
HCC cells, we employed cell migration and invasion
assays to determine these two key factors of malignant
progression and metastasis upon SSX2IP overexpression.
As shown in result, overexpression of SSX2IP led to sig-
nificantly enhanced migration and invasion of both
SMMC-7721 and BEL-7402 (Figure 4). Number of mi-
gratory SMMC-7721SSX2IP cell line is significantly higher
than the other two control groups (123.33 ± 9.45 vs
59.67 ± 4.73 and 51.33 ± 6.03), and number of invasive
SMMC-7721SSX2IP cell line is significantly higher
compared to the control groups (92.00 ± 7.00 vs 43.67 ±Table 3 Animal experiments for liver metastasis
Animal models Cells Cell numbers of injection Tim
Liver metastasis
Bel-7402 1 × 106 10
Bel-7402Vector 1 × 106 10
Bel-7402SSX2IP 1 × 106 104.16 and 38.00 ± 3.61, **P < 0.001, Figure 4A-B). Simi-
larly, number of migratory BEL-7402SSX2IP cell line is
significantly higher than the other two control groups
(154.67 ± 14.05 vs 103.67 ± 10.70 and 109.00 ±7.55), and
number of invasive BEL-7402SSX2IP cell line is signifi-
cantly higher compared to the control groups (113.00 ±
6.56 vs 63.33 ± 11.50 and 60.67 ± 11.02, *P < 0.01,
Figure 4C-D). These results displayed an enhanced effect
of SSX2IP on hepatocellular carcinoma cells migration
and invasion.SSX2IP reduces the sensitivity of hepatocellular
carcinoma cells to chemotherapeutic drugs
The positive effect of SSX2IP on HCC cells’ metastatic
status prompted us to speculate that it may also con-
tribute to the drug resistance of HCC cells. To test
this idea, we assayed chemosensitivity to the two most
common chemotherapy drugs, 5-Fu and CDDP, to
compare SSX2IP overexpression groups (SMMC-
7721SSX2IP and BEL-7402SSX2IP) and the according
control groups (SMMC-7721, SMMC-7721Vector, BEL-
7402 and BEL-7402Vector). The results showed that the
IC50s of both 5-Fu and CDDP were significantly
increased by the overexpression of SSX2IP in both
SMMC-7721 and BEL-7402 lines (Figure 5). SMMC-
7721SSX2IP and BEL-7402SSX2IP for 5-Fu was 24.68 ±
1.17 μM and 28.52 ± 0.65 μM, respectively, while the
IC50s of SMMC-7721, SMMC-7721Vector, BEL-7402 and
BEL-7402Vector for 5-Fu were 14.59 ± 0.77 μM, 13.60 ±
0.88 μM, 12.73 ± 1.81 μM and 14.16 ± 1.20 μM (**P <
0.001, Figure 5A-B). The IC50s of SMMC-7721SSX2IP and
BEL-7402SSX2IP for CDDP were 11.38 ± 1.42 μM and 9.86
± 1.24 μM, respectively, while the IC50s of SMMC-7721,
SMMC-7721Vector, BEL-7402 and BEL-7402Vector for
CDDP were 5.72 ± 0.75 μM, 6.18 ± 0.81 μM, 6.13 ±
0.24 μM and 5.90 ± 0.47 μM, respectively (**P < 0.001,
Figure 5C-D). We could concluded that SSX2IP
contributes to reduce the sensitivity of HCC cells to
chemotherapeutic drugs.e No. of metastasis mice/No. of mice injected P
weeks 2/10
weeks 1/10 P = 0.023
weeks 7/10
Figure 3 SSX2IP enhances scratch wound healing ability of hepatocellular carcinoma cells. A. Movement ability of SMMC-7721, SMMC-
7721Vector and SMMC-7721SSX2IP cell lines was detected by scratch wound healing assays. B. Movement ability of BEL-7402, BEL-7402Vector and
BEL-7402SSX2IP cell lines was detected by scratch wound healing assays. By wound distance analysis, the movement ability of HCC cells was
enhanced by SSX2IP.
Li et al. Journal of Translational Medicine 2013, 11:52 Page 6 of 9
http://www.translational-medicine.com/content/11/1/52Discussion
Statistical analysis of pathological features and
postoperative survival of clinical cases of hepatocellular
carcinoma patients demonstrated that tumor with
SSX2IP high expression had inclinations towards larger
tumor size and more tumor thrombus. Patients with
high SSX2IP expression experienced significantly shorter
periods of postoperative survival. These data indicatedFigure 4 SSX2IP promotes migration and invasion of hepatocellular c
invasive SMMC-7721 cells on the membrane (magnification, 100×). B. Avera
Representative photographs of migratory or invasive BEL-7402 cells on the
invasive BEL-7402 cells (*P < 0.01). The data represent the mean ± s.d. of thrgreat significance of SSX2IP in the clinical research of
hepatocellular carcinoma.
Metastatic ability of hepatoma cells is the key factor
for HCC development. In intraperitoneal injection and
tail vein injection experiments in nude mice, over-
expression of SSX2IP can promote intraperitoneal
spreading and formation of liver metastases. In vitro
studies, scratch wound healing assay and transwellsarcinoma cells. A. Representative photographs of migratory or
ge number of migratory or invasive SMMC-7721 cells. (**P < 0.001). C.
membrane (magnification, 100×). D. Average number of migratory or
ee independent experiments.
Figure 5 SSX2IP reduces the sensitivity of hepatocellular carcinoma cells to chemotherapeutic drugs. A. Dose–response curves and IC50
values for 5-Fu between SMMC-7721, SMMC-7721Vector and SMMC-7721SSX2IP cell lines. B. Dose–response curves and IC50 values for 5-Fu between
BEL-7402, BEL-7402Vector and BEL-7402SSX2IP cell lines. C. Dose–response curves and IC50 values for CDDP between SMMC-7721, SMMC-7721Vector and
SMMC-7721SSX2IP cell lines. D. Dose–response curves and IC50 values for CDDP between BEL-7402, BEL-7402Vector and BEL-7402SSX2IP cell lines. The IC50
values of SMMC-7721SSX2IP and BEL-7402SSX2IP cell lines for 5-Fu and CDDP are higher, compared to those in control groups (**P < 0.001).
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motility of tumor cells to reflect their ability to penetrate
extracellular matrix and to migrate. Hepatoma cells with
high expression of SSX2IP were shown a very strongmobility, and the number of cells which had penetrate
the filter membrane in this group was significantly
higher than in the parental and empty vector-transfected
groups. These results suggest that SSX2IP could
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cells.
The dynamic changes of cell adhesion characteristics
and the reorganization of cytoskeletal play important roles
in the process of tumor invasion and metastasis [17,18].
ADIP, the homologous gene of SXX2IP in rodents,
localizes at cell-cell adherent junctions and binds to α-
actinin, a kind of F-actin-bundling protein. ADIP may play
a key role in the organization of the cytoskeleton at cell-
cell adherent junctions and may connect the nectin-afadin
and E-cadherin-catenin systems [15]. These systems have
been shown to maintain the epithelial to mesenchymal
transition (EMT) and mesenchymal-epithelial transition
(MET), and studies of a variety of tumors have revealed
that this conversion characteristics of the tumor cells is an
important reason for the tumor metastasis and recurrence
[19-21]. Therefore, it is suggested that SSX2IP may regu-
late the EMT-MET by affecting E-cadherin-catenin
systems and thereby promote the invasion and metastasis
of tumor cells.
On the other hand, ADIP has been shown to promote
cell movement by regulating the activation of Rac1 [16].
Rac1 belongs to the Rho family and the Ras superfamily of
small GTP-binding proteins, and it is an important regula-
tor which connects membrane surface receptors and actin
cytoskeleton and plays a role of molecular switch.
Members of Rho family regulate the actin assembly and
affect cell movement, tumor invasion and migration [22].
The guanine nucleotide exchange factor specific to Rac1
can regulate cytoskeleton reorganization, affect cell polar-
ity and promote cell motility and migration by promoting
the conversion of Rac-GDP (inactivation) to Rac1-GTP
(activation) [23]. As our study indicated a role of SSX2IP
in promoting the mobility of HCC cells, we speculated
that SSX2IP may do so via activating Rac1. We are actively
investigating the influence of SSX2IP on Rac1 activation.
Chemotherapy plays an irreplaceable role in the clin-
ical treatment of HCC [24]. However, resistance of hepa-
toma cells to chemotherapy drugs often makes
chemotherapy unsatisfactory [25]. High expression of
some resistance related genes in tumor cells is the
underlying cause of drug resistance that eventually leads
to ineffective treatment. Our data showed SSX2IP
reduced the sensitivity of hepatoma cells to 5-Fu and
CDDP and significantly increased IC50, which indicated
that SSX2IP may be a resistance related gene with the
ability to promote the resistance of hepatoma cells to
chemotherapeutic drug. Although the exact function of
SSX2IP in drug resistance is still unknown, clues can be
taken from its rodent homologue ADIP, which directly
binds to β’-COP to participate in the vesicle trafficking
from the Golgi apparatus to the endoplasmic reticulum
[26]. As is well known, many resistance genes encode
transporter proteins, such as ABCG2 in the ABC proteinfamily [27,28]. We speculate that SSX2IP is likely to be a
player in the intracellular transportation system.
Studies of SSX2IP in tumor-related fields have been
focused on leukemia in the past, while little is known
about its role in oncology of other types of cancers.
Our results suggest that SSX2IP can significantly pro-
mote the motility, invasion and migration of hepatoma
cells and improve their resistance to chemotherapeutic
drugs. Importantly, since SSX2IP has been identified as
an acute myeloid leukaemia-associated antigen and a
potential immunotherapy target for leukemia, this study
has expanded the usage of those SSX2IP related
applications to HCC. Further in-depth exploration of
the molecular mechanisms of SSX2IP in promoting the
migration, invasion and drug resistance of HCC will be
needed to clarify the role of SSX2IP in HCC develop-
ment and to provide theoretical basis for future clinical
applications.
Conclusions
Our studies showed that SSX2IP can promote the devel-
opment and metastasis of hepatocellular carcinoma. It
reduces the sensitivity of hepatocellular carcinoma cells
to chemotherapeutic drugs and could be a resistance-
associated gene. All the above, our findings suggest that
SSX2IP may serve as a new target for clinical diagnosis
and treatment of hepatocellular carcinoma.
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